Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - palonosetron hydrochloride, quantity: 280 microgram (equivalent: palonosetron, qty 250 microgram) - injection, solution - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - palonosetron injection is indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - palonosetron hydrochloride, quantity: 280 microgram (equivalent: palonosetron, qty 250 microgram) - injection, solution - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - palonosetron injection is indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - palonosetron hydrochloride, quantity: 280 microgram (equivalent: palonosetron, qty 250 microgram) - injection, solution - excipient ingredients: sodium acetate trihydrate; water for injections; mannitol; hydrochloric acid; sodium hydroxide - palonosetron injection is indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - palonosetron - vomiting; nausea; cancer - antiemetics and antinauseants, - palonosetron accord is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.palonosetron accord is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - palonosetron hydrochloride - nausea; vomiting; cancer - antiemetics and antinauseants, - palonosetron hospira is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy;the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.palonosetron hospira is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - netupitant, quantity: 300 mg; palonosetron hydrochloride, quantity: 0.56 mg (equivalent: palonosetron, qty 0.5 mg) - capsule - excipient ingredients: microcrystalline cellulose; sucrose laurate; povidone; croscarmellose sodium; purified water; silicon dioxide; sodium stearylfumarate; magnesium stearate; glyceryl caprylate/caprate; glycerol; polyglyceryl-3 dioleate; butylated hydroxyanisole; nitrogen; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; ethanol absolute; iron oxide black; sorbitol; 1,4-sorbitan; mannitol - akynzeo is indicated in adult patients for: prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - palonosetron hydrochloride, quantity: 280 microgram (equivalent: palonosetron, qty 250 microgram) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium citrate dihydrate; sodium hydroxide; mannitol; disodium edetate; citric acid monohydrate - palonosetron baxter is indicated for:,? prevention of nausea and vomiting induced by cytotoxic chemotherapy,? prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery.

Israel - English - Ministry of Health

teva israel ltd - palonosetron as hydrochloride - solution for injection - palonosetron as hydrochloride 0.05 mg/ml - palonosetron - palonosetron teva is indicated in adults and in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - palonosetron hydrochloride, quantity: 56 microgram/ml - injection, solution - excipient ingredients: mannitol; water for injections; citric acid monohydrate; sodium citrate dihydrate - palonosetron is indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.

United States - English - NLM (National Library of Medicine)

sandoz inc - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - palonosetron 0.25 mg in 5 ml - palonosetron injection is indicated in adults for prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). - acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (hec). - postoperative nausea and vomiting (ponv) for up to 24 hours following surgery. efficacy beyond 24 hours has not been demonstrated. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, palonosetron is recommended even where the incidence of postoperative nausea and/or vomiting is low. palonosetron hcl injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: • acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemoth